Payal Rana of Fortville carries a unique perspective on vaccines and personal health decisions, one born out of a terrifying ...
After being told he might not walk for two years, the longtime Little League football coach fought through treatment to ...
WAYNE, Pennsylvania (WPVI) -- One step at a time, those who are diagnosed with rare neuropathic conditions such as GBS or CIDP prove it's possible to get back on their feet. A great place to see their ...
Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy that can lead to severe weakness of the limbs, face, and respiratory muscles. Its pathophysiology involves autoantibodies that attack ...
ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...
First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) ...
Target Enrollment Achieved in Phase 3 Pivotal Study of ANX005 in GBS Representing the Company’s Third Successfully Executed Clinical Study in GBS Company on Track to Report Pivotal Data in the First ...
RSV infection in adults ≥65 is linked to rare but elevated Guillain-Barré syndrome risk, particularly in those aged ≥75 years ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback